The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

LOOK AT SNAP COMPARISON TO FACEBOOK, TWITTER AND GOPRO TO SEE IF IT WILL GO TO $10 OR $100 AND HOW TO TRADE $SNAP $TWTR $FB $GPRO $GOOG $GOOGL

March 3, 2017

Snap, the parent of Snapchat, is the hottest initial public offering of the year. The company’s shares were listed this week at $17 and recently traded at $27. So investors are naturally asking me: How do I trade Snap SNAP? Will Snap become successful like Facebook FB? Will Snap’s stock shoot up like Twitter’s TWTR only to fizzle? Since Snap is marketing itself as a video-camera company, is a comparison to GoPro’s GPRO, IPO appropriate? Let me first share with you how we are trading Snap for the short term at The Arora Report. Then I’ll compare Snap to those

Read More »

SNAP: PARTIAL PROFITS TAKEN, RAISE STOPS ON THE REST $SNAP

March 3, 2017

This post was just published on ZYX Buy Change Alert. Partial profits have been taken as the stock moved to our target zones given over an hour before the stock started trading. Since it is a trading position we have raising stops on one half of the longer term position to $23 to $23.38 and the remaining to $19.11 to $19.38. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance

Read More »

WEEKLY MARKET DIGEST: MOM & POP GIDDY BUT PROFESSIONALS CAUTIOUS, SMART MONEY SELLS SILVER $DIA $GLD $QQQ $SLV $SPY $TBF $TBT $USO

March 3, 2017

   Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section What To Do Now. 88% RATE RISE ODDS, FED SPEAK AHEAD, SMART MONEY SELLS SILVER March 3, 2017 This is what you need to know today. 88% Rate Rise

Read More »

SNAPCHAT OPENING INDICATION $SNAP

March 2, 2017

This post was just published on ZYX Buy Change Alert. SNAP IPO priced at $17 per share.  The preliminary opening indication is $22. Consider stops on one-third in the zone of $19.23 to $19.38, on another third $18.63 to $18.68, and on the remaining third $16.87 to $16.97. Consider targets in the following zones: 10% tranche  $23 to $24.73, 10% tranche  $26 to $26.73, 10% tranche  $28 to $28.43   You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a

Read More »

HERE’S THE REAL REASON BEHIND DOW 21,000 (NO, IT’S NOT TRUMP’S SPEECH) $DIA $SPY $QQQ $IWM $YM_F

March 1, 2017

As I write this, the Dow Jones Industrial Average DJIA,  has surged more than 300 points, vaulting the benchmark index over 21,000 points for the first time. This ferocious rally, a day after President Trump’s speech to Congress, also is reflected in other indices, including the S&P 500 Index SPX,  and the Nasdaq 100 NDX. Stock market gurus are out in full force explaining the reasons for the rally. But I have not heard the real reason from a single person. To get to the answer, let’s start by reviewing an annotated chart of DJIA futures YMH7.  Please click here for the

Read More »

BIOTECH BEAR ETF LABD: TRUMP SAYS DRUG PRICES MUST BE REDUCED IMMEDIATELY $LABD

March 1, 2017

This post was just published on ZYX Buy Change Alert. In his speech, Trump said that drug prices must be reduced immediately.  The short squeeze is so powerful that the market is ignoring what Trump said.  For this reason, the stop zone is being changed on LABD to $7.00 – 8.38.  Due to the short squeeze we are  not adding here.  The plan is to add more and tighten the stop, perhaps tomorrow. Please be aware that due to the short squeeze, the risk in this trade has significantly increased.  You may need to make adjustments to the quantity held based on your personal

Read More »

TAKE PARTIAL PROFITS ON MYLAN $MYL

February 28, 2017

This post was just published on ZYX Buy Change Alert. MYL is long from an average price of $37.78.  As of this writing it is trading at $41.97.  Consider taking profits on a 15% tranche in the zone of $41.23 to $44.73.  Consider a stop on the remaining in the zone of $39.23 to $39.43.   You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear

Read More »

BIOTECH BEAR ETF LABD: FUND MOVES INTO BIOTECHS AFTER LIQUIDATING PRECIOUS METAL STOCKS $LABD $XBI $IBB $GDX $GDXJ $DUST $NUGT

February 28, 2017

This post was just published on ZYX Buy Change Alert. Please see the Morning Capsule for apparently a fund moving money from liquidating precious metal stocks into biotechs.  This explains the move lower in LABD. The real reason for holding is a potential Trump tweet or mention in his speech tonight of drug prices.  In our analysis, the probability of Trump mentioning drug prices in tonight’s speech is low.  However as the Congress moves towards repeal of Obamacare, details may have a negative impact on biotechs and pharmaceuticals. LABD buy zone remains $9.50 to $12.52.  First target remains $19.50 to $20.  The second

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content